文献速递胸部肿瘤放疗放疗物理与技术

III期非小细胞肺癌同步放化疗中不同放疗技术比较

A Comparison of Radiation Techniques in Patients Treated With Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2020-01-29

该研究基于加拿大安大略省2009至2017年接受同步放化疗的3872例III期非小细胞肺癌患者,回顾性比较3DCRT、IMRT与VMAT的总生存。

要点

  • 研究期间3DCRT使用下降、VMAT使用增加
  • 结合剂量学优势,推荐III期NSCLC采用IMRT或VMAT

核心结论

  • 接受IMRT或VMAT的患者与3DCRT相比生存未受损害,结合潜在剂量学优势推荐IMRT和VMAT用于III期NSCLC同步放化疗。

研究设计与样本

  • 基于人群的回顾性队列研究,纳入2009至2017年加拿大安大略省接受同步放化疗的III期NSCLC患者共3872例。
  • 按放疗技术分为3DCRT组1178例、IMRT组1847例、VMAT组847例。
  • 主要结局为总生存,采用Kaplan-Meier法计算并用log-rank检验比较,Cox回归校正协变量。

主要发现

  • 中位生存期:3DCRT组21.2个月(95%CI 20.0-22.8),IMRT组23.9个月(95%CI 22.3-25.6),VMAT组24.9个月(95%CI 22.5-27.4)。
  • 研究期间观察到3DCRT使用减少、VMAT使用增加的趋势。

临床怎么用

  • III期NSCLC同步放化疗可优先选择IMRT或VMAT,不必担心生存劣于3DCRT。
  • 临床选择技术时可结合IMRT/VMAT的剂量学优势进行个体化决策。

局限性

  • 回顾性队列设计可能存在选择偏倚和混杂因素。
  • 原文未报告具体混杂变量校正细节及剂量学参数。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The standard of care in management of patients with good performance status and unresectable stage III non-small cell lung cancer (NSCLC) therapy is concurrent chemoradiation. Newer techniques such as intensity modulated radiation therapy (IMRT) and volumetric modulated arc therapy (VMAT) are replacing 3-dimensional conformal radiation (3DCRT) despite low-quality evidence of improved outcomes. We used population-based data to examine survival outcomes by radiation technique. METHODS AND MATERIALS: A population-based retrospective cohort of patients with stage III NSCLC treated with concurrent chemoradiation from 2009 to 2017 in Ontario were identified. The primary outcome was a comparison of overall survival among 3DCRT, IMRT, and VMAT, calculated using the Kaplan-Meier method and compared using log-rank test. Cox regression was used to investigate effect of radiation type on overall survival adjusted for other covariates. RESULTS: A total of 3872 patients were treated with 3DCRT (n = 1178), IMRT (n = 1847), or VMAT (n = 847). A decline in 3DCRT and increase in VMAT use were observed over time. Median survival in months was 21.2 (95% confidence interval [CI], 20.0-22.8) for 3DCRT, 23.9 (95% CI, 22.3-25.6) for IMRT, and 24.9 (95% CI, 22.5-27.4) for VMAT, but these differences were not statistically significant (P = .06). CONCLUSIONS: Our study demonstrates that survival is not compromised in patients receiving IMRT or VMAT (compared with 3DCRT). Thus, given the potential dosimetric advantages associated with these techniques, VMAT and IMRT are recommended for the management of patients with stage III NSCLC.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Peng J, Pond G, Donovan E, et al. A Comparison of Radiation Techniques in Patients Treated With Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2020. PMID: 32007366. doi:10.1016/j.ijrobp.2019.12.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。